Home > Research projects >Projects in Clinical Studies

The Introduction of Hemay005

Hemay005, a PDE4 inhibitor, is a proprietary new chemical entity being developed for treatment of Psoriasis.

Psoriasis, a type of chronic skin disease, has a prevalence of .75% to 2.9% in Europe, less than a 1% chance in Asia and less than .5% in China. The prevalence and morbidity rates are increasing every year [1].With Psoriasis having a direct impact on the physical and mental health of a patient, there is an urge for a successful treatment method.

Current treatments options include topical medication, physical therapy, and systematic treatments, such as biological agents. However, these current methods have a very limited impact while still creating an array of side effects, promoting the need for this new therapeutic agent to address this medical condition.

Based on the preliminary preclinical evidence, Hemay005 has shown the potential to become a successful treatment option for those diagnosed with Psoriasis. Hemay005 is currently being investigated through clinical trials in China.

 

References:

[1] Wu C, Jin HZ. Research progress on epidemiology of Psoriasis. International Journal of Dermatology and Venereology, 2013392):97 - 100.

 

All rights reserved (2017), tianjin ICP for 05010040